Intravenous Ibuprofen (Ibu) for the Treatment of Patent Ductus Arteriosus(pda) in Preterm Infants With Respiratory Distress Syndrome (Rds). † 1486

Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus

“…From our data, ibuprofen, unlike other NSAIDs such as mefenamic acid [35] and aspirin [36], resulted pharmacologically as efficient as indomethacin in the treatment of PDA and could be an alternative to indomethacin in prematures: this confirms what seen by other authors [23][24][25][26][27]37] in the few studies available in literature about ibuprofen administration to neonates with PDA.…”

Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants

“…Data for two trials were reported in abstract form only 20 21. Three trials were translated from foreign language papers with English abstracts 22–24. Randomisation was adequately described in eight trials; and allocation concealment, in five 22–31.…”

Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?

“…Search results and citation lists for prior publications identified 75 randomized-controlled trials of interventions that close a PDA in preterm infants. In 26 trials (five comparing long and short courses of indomethacin, [37][38][39][40][41] 19 comparing indomethacin and ibuprofen, [42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60] and two that included very early crossover to treatment of nonresponders 29,61 ), rates of ductal closure did not differ between treatment assignments, precluding evaluation of effects of ductal closure on other outcomes, so these were excluded. The remaining 49 trials, 36, including 4728 subjects, were deemed potentially informative, as all but one documented substantial reduction in ductal patency after treatment.…”